Club Biomed

08/19/2015

We followed a company trying to bring a drug with similar indications for years, but it never made it to market.

The drug has faced criticism from those who say the F.D.A. was pressured. But advocates say the move was long overdue, given the options available to men.

03/07/2015

We have been watching and wondering how long this would take. Now we know.

The approval paves the way for alternatives to an entire class of complex and costly drugs to go on the market.

12/24/2014

Happy Holidays.

12/04/2014

One of Biomed's original stocks.

Biogen Idec Inc. (BIIB) Is Soaring On Positive Alzheimer's Study Results (RTTNews.com) - Biogen Idec Inc. (BIIB) announced interim phase 1b results

08/31/2014

A new class of cholesterol drugs: I see many interesting developments.

Sanofi and Regeneron Pharmaceuticals Inc.’s cholesterol drug cut levels of the heart disease-causing fat in four studies, and there are early indications it may prevent death and heart attack.

08/21/2014

Will this anti-Ebola strategy work? An investment opportunity?

Researchers said the experimental treatment kept monkeys alive in a study even after the Marburg virus was already detectable in the animals’ blood.

08/14/2014

“Politicians are a lot like diapers. They should be changed frequently — and for the same reasons.” — Robin Williams as Tim Dobbs in “Man of the Year” (2006)

08/14/2014

Interesting science? potential profits?

Options include experimental treatments that have never before been tested on people and some of the world’s most widely used drugs.

08/07/2014

Balancing risk and reward is a tricky proposition, whether it is a therapeutic or a recreational drug.

An economic analysis buried in regulations requires weighing public benefits against the happiness smokers might lose in quitting.

03/24/2014

Anyone want to bet that this will be full immediately after it is opened?

Providing start-up lab space, Harlem Biospace is an effort to tap the scientific talent and entrepreneurial spirit of Columbia University and City College.

03/06/2014

The motley Fool on designer organisms.

Many investors are captivated by the future of companies such as Tesla Motors and 3-D Systems -- and the potential creation of shareholder value on a scale that will be difficult to match. But are investors overlooking an even more promising industry with a brighter future? - Maxx Chatsko - Energy

01/03/2014

Is Biomedical Reseach's future in Asia?
Thursday’s issue of the New England Journal of Medicine contained a perspective article, “Asia’s Ascent – Global Trends in Biomedical R&D Expenditures.” The authors conclude “…that U.S. inflation-adjusted R&D expenditures and the U.S. share of global expenditures decreased from 2007 through 2012…Moreover, the decline was driven almost entirely by reduced investment by industry, not the public sector, between 2007 and 2012. Sequestration of NIH funding in 2013 and beyond will exacerbate this reduction…” The authors also stated that the data “…suggests that industry is simply reallocating R&D funding to Asia-Oceania.”

Perspective from The New England Journal of Medicine — Asia's Ascent — Global Trends in Biomedical R&D Expenditures